Loading
The first bispecific ADC to extend both progression-free and overall survival in oesophageal cancer, for patients whose immunotherapy has stopped working.
Interim analysis met dual primary endpoints of OS and BICR-assessed PFS (announced February 2026; presented ASCO 2026). 249 vs 248 patients. Second-line ESCC previously had only single-agent chemotherapy (irinotecan, taxanes) with median OS under a year. Global confirmatory trials are being planned.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
497 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Izalontamab brengitecan | - | 9.8 months | 0.64 (0.49 to 0.83) | 0.0004 | link |
| Chemotherapy (physician's choice) | - | 7.2 months | ||||
| Progression-free survival (BICR)primary | Izalontamab brengitecan | - | 4.2 months | 0.5 (0.4 to 0.63) | <0.0001 | link |
| Chemotherapy (physician's choice) | - | 2 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/